MorphoSys Enters into Business Combination Agreement to be acquired by Novartis for EUR 2.7 Billion Equity Value

Germany - MorphoSys AG today announced the company entered into a Business Combination Agreement with Novartis data42 AG and Novartis AG based on Novartis' intention to submit a voluntary public...

Related Keywords

Canada ,United States ,Massachusetts ,Germany ,Boston ,Planegg ,Bayern ,German ,Thomas Biegi ,Julia Neugebauer ,Jean Paul Kress ,German Federal Financial Supervisory Authority Bafin ,Company Annual Report On Form ,Lymphoma Society ,Drug Administration ,Constellation Pharmaceuticals Inc ,Xencor Inc ,Exchange Commission ,Incyte Corporation ,Novartis ,Nasdaq ,Business Combination Agreement ,Purchase Agreement ,Supervisory Board ,Paul Kress ,Chief Executive Officer ,Certain Cash Value ,New Opportunities ,German Securities Acquisition ,Takeover Act ,Federal Financial Supervisory Authority ,Tender Offer Statement ,Recommendation Statement ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Takeover Offer ,Annual Report ,Takeover Offer Documents ,News Publishing ,Markets ,